Results 21 to 30 of about 117,631 (302)

Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma [PDF]

open access: yes, 2015
The prevalence of global obesity is increasing. Obesity is associated with general cancer-related morbidity and mortality and is a known risk factor for development of specific cancers.
Alfraidi, Albandri   +5 more
core   +2 more sources

The Emerging World of JAK Inhibitors

open access: yesNepal Journal of Dermatology, Venereology & Leprology
The Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several ...
Shraddha Uprety
doaj   +3 more sources

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

open access: yesBMC Infectious Diseases, 2021
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz   +6 more
doaj   +1 more source

Future therapeutic targets in rheumatoid arthritis? [PDF]

open access: yes, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu   +154 more
core   +1 more source

Regulation of anti-inflammatory gene expression in vascular endothelial cells by EPAC1 [PDF]

open access: yes, 2015
Suppressor of cytokine signalling 3 (SOCS3) is a potent inhibitor of pro-inflammatory pathways involved in atherogenesis and the development of neo-intimal hyperplasia (NIH), which contributes to the in-stent re-stenosis responsible for the failure of ...
Palmer, Timothy P., Yarwood, Stephen J.
core   +1 more source

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders

open access: yesPharmacological Research, 2022
The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj   +1 more source

Targeting STAT3 in Cancer with Nucleotide Therapeutics. [PDF]

open access: yes, 2019
Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an "undruggable" target for ...
Grandis, Jennifer R   +3 more
core   +2 more sources

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

open access: yesHepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou   +15 more
wiley   +1 more source

Janus kinase inhibitors: jackpot or potluck?

open access: yesOncology Reviews, 2012
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat   +1 more
doaj   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

open access: yesHepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy